The researchers found that the use of GLP-1 receptor agonists significantly reduced the risk of 42 different health conditions, including psychotic disorders, infections, and dementia.
Assistant Prof Ziyad Al-Aly noted that while the benefits were evident in diabetic patients, it's plausible non-diabetic individuals might also see similar advantages, subject to weight loss factors.
The team’s study, considered the most comprehensive of its kind, analyzed health outcomes of GLP-1RA users compared to individuals receiving standard diabetes care over roughly three and a half years.
Despite the beneficial outcomes observed, the research indicated that certain risks, like arthritic disorders, could be heightened with GLP-1RAs, which underscores a need for cautious evaluation.
Collection
[
|
...
]